Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using (177)Lu-FAP-2286: First-in-Humans Results

Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides for theranostic applications. We present the first-in-humans results using (177)Lu-FAP-2286 fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Baum, Richard P., Schuchardt, Christiane, Singh, Aviral, Chantadisai, Maythinee, Robiller, Franz C., Zhang, Jingjing, Mueller, Dirk, Eismant, Alexander, Almaguel, Frankis, Zboralski, Dirk, Osterkamp, Frank, Hoehne, Aileen, Reineke, Ulrich, Smerling, Christiane, Kulkarni, Harshad R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2022
Materias:
Featured Article of The Month
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978187/
https://www.ncbi.nlm.nih.gov/pubmed/34168013
http://dx.doi.org/10.2967/jnumed.120.259192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978187/
https://www.ncbi.nlm.nih.gov/pubmed/34168013
http://dx.doi.org/10.2967/jnumed.120.259192

Ejemplares similares